There are 702 resources available
22P - Analyzing recurrence in colorectal cancer: Is a five years follow-up enough?
Presenter: Belén de Frutos González
Session: Poster Display session
23P - Renal impairment evaluation on postoperative (adjuvant) chemotherapy for colon cancer
Presenter: Aleksandra Gladys
Session: Poster Display session
24P - Standardizing data collection in adjuvant colon cancer trials: A consensus project from the IDEA and ACCENT international consortia and national experts
Presenter: Debora Basile
Session: Poster Display session
25P - PROgnostic Signature in stage II colon cancer (CC) patients enrolled in the phase III clinical trial TOSCA: PROSIT study
Presenter: Alberto Puccini
Session: Poster Display session
26P - Response in patient-derived models recapitulates circulating tumor DNA clearance of matched colon cancer patients after adjuvant treatment in the PEGASUS trial
Presenter: Luca Lazzari
Session: Poster Display session
28P - A mixed methods longitudinal process evaluation and implementation study of ctDNA use to guide adjuvant chemotherapy decision-making in patients with colorectal cancer: A sub-study of the ongoing UK wide interventional TRACC part C trial
Presenter: Naureen Starling
Session: Poster Display session
29P - Characterization of T cell responses induced by the individualized mRNA neoantigen vaccine autogene cevumeran in adjuvant stage II (high risk)/stage III colorectal cancer (CRC) patients (pts) from the biomarker cohort of the phase II BNT122-01 trial
Presenter: Maria Elena Elez Fernandez
Session: Poster Display session
30P - Immunological markers of pathological and clinical and outcomes in mismatch repair deficient (MMRd) colorectal cancer (CRC)
Presenter: Benjamin Challoner
Session: Poster Display session
31P - Effect of fruquintinib in patients with heavily pretreated metastatic colorectal cancer according to prognostic factors at baseline: Exploratory analysis of FRESCO-2
Presenter: Dirk Arnold
Session: Poster Display session
32P - Patient-reported tolerability of sotorasib (soto) and panitumumab (pani) versus trifluridine/tipiracil (T/T) or regorafenib (rego) in patients (pts) with metastatic colorectal cancer (mCRC) in the CodeBreaK 300 study
Presenter: Julien Taieb
Session: Poster Display session